As it waits for an FDA decision on one non-opioid pain drug, Viatris has its eye on two more, via a takeover bid for Pacira ...
Matchpoint Therapeutics is preparing to take its oral T cell modulator through proof-of-concept clinical testing in ...
US pharma trade organisation PhRMA is challenging the Trump administration's GLOBE model for Most-Favoured Nation (MFN) ...
Raising funding, assembling the initial team, building lab operations from the ground up, generating proof-of-concept ...
Pfizer acquired Tukysa as part of its $43 billion takeover of Seagen in 2023, three years after the drug first reached the US ...
The Nobel Prize in Chemistry 2026 has been awarded to two scientists - Henri B Kagan and Kensō Soai – for discoveries on ...
Eli Lilly has revealed the fourth new manufacturing site in its $27 billion capital investment spree in the US – a $3.5 billion facility in Lehigh Valley, Pennsylvania. The company said the site will ...
The new study is the first readout for a drug added by the Forte takeover, which closed in August, and will relieve some of ...
Exclusive analysis for World Health Expo (WHX) by Frost & Sullivan forecasts precision medicine growth of more than 10% in ...
MSD has been rocked by a court judgment ordering it to stop manufacturing and selling its subcutaneous formulation of cancer ...
Just months after launching an open-source 'virtual biology' platform, non-profit research organisation Biohub has raised ...
Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include a second indication, symptomatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results